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Objective: To investigate the impact of reduced adipocyte fatty acid-binding protein 4 (FABP4) in control of body weight,
glucose and lipid homeostasis in diet-induced obese (DIO) mice.
Methods: We applied RNA interference (RNAi) technology to generate FABP4 germline knockdown mice to investigate their
metabolic phenotype.
Results: RNAi-mediated knockdown reduced FABP4 mRNA expression and protein levels by almost 90% in adipocytes of
standard chow-fed mice. In adipocytes of DIO mice, RNAi reduced FABP4 expression and protein levels by 70 and 80%,
respectively. There was no increase in adipocyte FABP5 expression in FABP4 knockdown mice. The knockdown of FABP4
significantly increased body weight and fat mass in DIO mice. However, FABP4 knockdown did not affect plasma glucose and
lipid homeostasis in DIO mice; nor did it improve their insulin sensitivity.
Conclusion: Our data indicate that robust knockdown of FABP4 increases body weight and fat mass without improving glucose
and lipid homeostasis in DIO mice.
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Introduction
Fatty acid-binding proteins (FABPs) are a family of conserved
proteins that bind medium to long-chain fatty acids and are
believed to coordinate lipid response in cells.
1–3 Fatty acid-
binding proteins not only facilitate long-chain fatty acid
(LCFA) transport and metabolism, but also act as signaling
molecules to sequester or distribute LCFA to regulate
signaling pathways and gene expression. Recent studies
demonstrated that dysregulated fatty acid metabolism and
signaling have a crucial role in the etiology of metabolic
syndrome. Both in vitro and in vivo studies showed that
FABPs seem to be central in the regulation of fatty acid
metabolism.
1–3 However, the exact mechanisms by which
FABPs regulate different biological functions are not well
understood.
There are nine members of the FABP family, and each of
them shows a distinct tissue expression pattern.
1–3 Several
lines of evidence indicate that adipocyte FABP (FABP4 or
adipocyte protein 2 (aP2)), which is also expressed in
macrophages, contributes to the development of several
aspects of metabolic syndrome.
4–7 Mice with genetic disrup-
tion of FABP4 are protected against diet-induced insulin
resistance despite the development of more severe obesity.
4
Genetic disruption of FABP4 in obese diabetic mice (ob/ob)
significantly reduces blood glucose levels and improves
insulin sensitivity concomitant with increased body weight.
7
These mice are also reported to have improved plasma lipid
profile with the reduction in plasma triglyceride (TG)
and cholesterol levels. Complete knockout of FABP4 or
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mice leads to marked protection against the development
of atherosclerosis.
5 Although FABP4 is the major FABP in
adipocytes, another FABP protein (FABP5 or keratinocyte
lipid binding protein (MAL1)) is also found in these cells.
8 As
genetic disruption of FABP4 significantly increases FABP5
expression, it was difficult to formally determine which
aspects of the FABP4 knockout phenotype were due to the
loss of FABP4 or upregulation of FABP5.
4 Additional studies
demonstrated that genetic disruption of FABP5 mildly
improves insulin sensitivity in diet-induced obesity with a
concomitant reduction in body weight.
9 Furthermore, FABP5
knockout mice on an ob/ob background demonstrate a mild
improvement in insulin sensitivity without an alteration in
body weight. In contrast, transgenic mice with overexpres-
sion of FABP5 in adipocytes develop glucose intolerance.
9
Genetic disruption of both FABP4 and FABP5 (double
knockout) has a more profound metabolic effect in different
animal models of insulin resistance than the ablation of only
one isoform.
10,11 Double knockout mice show a marked
improvement in insulin sensitivity and significant resistance
to diet-induced obesity.
11 Double knockout mice on an
ob/ob background demonstrate improved insulin sensitivity
and protection from hepatic steatosis.
10 These studies
indicate that FABP4 and FABP5 both have an important role
in the development of insulin resistance. They also suggest
that blocking the function of FABP4 and FABP5 could
provide significant efficacy in reversing pathologies of
nutrient metabolism. Indeed, a small molecule that has
been shown to inhibit the binding of a fluorescently labeled
fatty acid to FABP4 has been reported to reduce plasma
glucose levels, improve insulin sensitivity and improve
glucose tolerance without affecting body weight in ob/ob
mice.
12
Although total genetic disruption may generally serve as the
best means to determine the function of a gene, it may not
always be the best method to predict the biological outcome of
pharmacologically inhibiting the protein product of that gene.
For example, the statins, 3-hydroxy-3-methylglutaryl–coen-
zyme A reductase inhibitors, have been proven to be clinically
safe and efficacious as antiatherosclerosis therapy, whereas
genetic disruption of 3-hydroxy-3-methylglutaryl–coenzyme A
reductase in mice results in embryonic lethality. Similarly,
genetic disruption of FABP4 leads to a robust increase in FABP5
expression,
4 which makes it difficult to determine whether the
phenotype observed in FABP4 knockout mice is due to the loss
of FABP4 or gain of FABP5 function.
Of late, RNA interference (RNAi) has become a powerful
tool to understand gene function. Systemic delivery of RNAi
in mice can effectively knockdown target gene in liver by
different means.
13,14 However, knockdown of target gene in
adipose tissue in vivo by RNAi remains challenging. To better
predict the potential on-target effect of FABP4 pharmacolo-
gic inhibitors, we applied RNAi technology to generate a
whole-body knockdown model of this FABP. In this study, we
report the phenotypic characterization of this mouse line.
Materials and methods
FABP4 RNAi and shRNA
In preliminary studies, an RNAi sequence specific for mouse
FABP4 was shown to effectively knockdown FABP4 expres-
sion in NIH3T3 cells. The sense sequence for the FABP4 RNAi
contains 19 nucleotides: 50-CACCGAGATTTCCTTCAAA-30.
To create a short hairpin RNA (shRNA), a nine-nucleotide
loop (5’-TTCAAGAGA-3’) was placed to separate the sense
and antisense sequences for RNAi.
Animals
The entire FABP4 shRNA described above was integrated into
Rosa26 in 129S6 C 5 7 B L / 6F 1m o u s ee m b r y o n i cs t e mc e l l sb y
TaconicArtemis (Cologne, Germany) as described before.
15
Mice expressing FABP4 shRNA (shFABP4) were established and
then backcrossed to C57BL/6NTac mice for six generations. At
5–6 weeks of age, these mice were housed in a group of 3–4
mice under standard housing conditions on a 12/12-h light
and dark cycle. The mice were provided with ad libitum access
to water and a standard chow diet (TEKLAD 7012: 13.4% kcal
from fat; 3.41kcalg
 1; Harlan Teklad, Madison, WI, USA) until
8 weeks of age. At that time, half of the mice were switched to
a high-fat diet (HFD; D12492: 60% kcal from fat, 5.24kcalg
 1;
Research Diet, New Brunswick, NJ, USA) and continued for
another 11 weeks. Body weight and food intake were
monitored weekly. Body fat composition was analyzed using
a Fat/Lean Mice Whole Body Magnetic Resonance Analyzer
(Brucker, Milton, ON, Canada) at week 11 of the HFD. Oral
glucose tolerance test was performed at week 11 on HFD
(under 4-h fasted condition) with a bolus glucose dose of
2gkg
 1 of body weight. After a 2-week recovery period, an
insulin tolerance test was performed with an intraperitoneal
injection of 0.5Ukg
 1 insulin (Humulin-R, Lilly, Indianapolis,
IN, USA). Blood glucose levels were monitored every 20min up
to 120min during the oral glucose tolerance test and insulin
tolerance test. After another 2-week recovery, ad libitum fed or
overnight fasted animals were killed and the liver, epididymal
fat and plasma were collected for further analysis. All animal
protocols used in these studies were approved by the Merck
Research Laboratories Institutional Animal Care and Use
Committee (Rahway, NJ, USA).
Plasma analysis
Glucose levels were analyzed from tail bleeds with a glucometer
(Lifescan, Milpitas, CA, USA). Plasma insulin levels were measured
with a commercial kit (ALPCO Diagnostics, Windham, NH, USA).
Plasma TG and free fatty acid levels were also measured with
commercial kits (TG (Cat: 11488872) and free fatty acid half
micro test (Cat: 11383175), Roche, Branford, CT, USA).
RNA isolation and analysis
Liver and adipose tissue were homogenized with the
Ultraspec RNA isolation kit (Biotecx, Houston, TX, USA).
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purification system (Qiagen, Valencia, CA, USA). The concen-
tration of RNA was estimated from absorbance at 260nm. The
expression levels of specific mRNAs were quantified using
quantitative fluorescent real-time PCR. The RNA was first
reverse transcribed using the iSCript cDNA synthesis kit
according to the protocol provided by the manufacturer
(Bio-Rad, Hercules, CA, USA). The amplification of each target
complementary DNA was then performed using TaqMan PCR
Reagent Kits in the ABI Prism 7900 Sequence Detection System
according to the protocols provided by the manufacturer
(PE Applied Biosystems, Foster City, CA, USA). All primer/
probe sets were selected from Applied Biosystems’ pre-devel-
oped TaqMan gene assays. The levels of mRNA were normal-
ized to the amount of GAPDH mRNA detected in each sample.
Tissue lysis and FABP4 ELISA
Adipose tissue was homogenized at a concentration of
150mgml
 1 in T-PER tissue protein extraction reagent
(Pierce, Rockford, IL, USA) supplemented with Halt protease
inhibitor cocktail (Pierce). Lysates were then centrifuged and
cleared supernatants were collected. Protein concentration
was determined using a Bradford assay (Pierce) and all
samples were normalized to 50mgml
 1. Samples were then
analyzed for FABP4 using a mouse Adipocyte FABP ELISA kit
(BioVendor, Candler, NC, USA) according to the man-
ufacturer0s protocol.
Plasma desaturation index analysis
Fatty acid methyl esters were generated by boiling 0.1ml of
plasma in 3ml of 5% methanolic HCl for 60min. Methyl
esters were extracted into hexane and then dried down under
nitrogen. Samples were resuspended in methanol. All samples
were analyzed using an Agilent 5975N-MSD equipped with an
Agilent 6890N GC system (Agilent technologies, Santa Clara,
CA, USA), and an HP-5MS capillary column (30m 
0.25mm 0.25mm). The temperature program was as follows:
1201C initial, increase by 101Cmin
 1 to 1651C, hold for
30min, increase by 51Cmin
 1 to 2101C, hold for 5min,
increase by 51Cmin
 1 to 2301C, hold for 7min. The split
ratio was 10:1 with a helium flow of 1mlmin
 1. Elution times
were as follows: palmitoleic acid methyl ester¼15.8min;
palmitic acid methyl ester¼16.2min; oleic acid¼18.3min;
and stearic acid methyl ester¼18.8min. The mass spectro-
meter was operated in the electron impact mode (70eV). The
instrument was operated in the scan mode from 50 to 320m/
z. Samples were analyzed in triplicate. A desaturation index
was calculated as the ratio of monosaturated fatty acid vs
saturated fatty acid levels.
Statistic analysis
Data are expressed as the mean±s.e.m. Statistical signifi-
cance was determined by using the unpaired Student0s t-test.
Statistical significance was assumed at Po0.05.
Results
Germline expression of FABP4 shRNA robustly knocks down
expression of FABP4 in adipose tissue
To obtain insight into the potential outcome of pharmaco-
logically inhibiting FABP4 function specifically, we gener-
ated a mouse germline knockdown model expressing FABP4
shRNA (shFABP4). Real-time PCR analysis showed that
shFABP4 knocked down FABP4 gene expression in adipose
tissue by 88% compared to wild-type (WT) mice on standard
chow (12±2 vs 100±15 arbitrary units (AUs), respectively;
Figure 1a). Wild-type diet-induced obese (DIO) mice that had
been fed an HFD, showed no difference in adipose tissue
FABP4 expression in comparison with standard chow-fed
(SC) mice. In DIO mice, shFABP4 knocked down adipose
tissue FABP4 expression by 70% compared with WT controls
(31±3 vs 103±8 AU, respectively). The HFD did not alter
FABP4 expression in WT mice compared with WT mice fed
with SC. However, HFD shFABP4 mice had a 2.5-fold increase
in FABP4 mRNA levels compared with shFABP4 mice fed
with SC, thereby resulting in only a 70% net diminution in
FABP4 mRNA expression in HFD rather than an 88%
reduction in SC mice (Figure 1a). Constitutive genetic
disruption of FABP4 has previously been reported to robustly
induce FABP5 expression. In contrast, knockdown of FABP4
by shRNA did not affect FABP5 expression in SC or DIO mice
(Figure 1b). The HFD feeding robustly increased FABP5
expression in adipose tissue by more than sixfold in WT
mice and ninefold in shFABP4 mice (Figure 1b). To confirm
that FABP4 protein levels were reduced in adipose tissue of
shFABP4 mice, we performed an ELISA of adipose tissue
lysates as described in the ‘Materials and methods’ section.
Consistent with our gene expression analysis results,
shFABP4 diminished adipose tissue FABP4 protein levels by
88% (0.12±0.02 vs 1±0.16 AU) in SC mice (Figure 1c), and
by 77% (0.21±0.04 vs 0.9±0.16 AU) in DIO mice. There was
no change in FABP4 protein levels between WT SC mice
and WT DIO mice. However, DIO shFABP4 mice displayed a
1.8-fold elevation in adipose tissue FABP4 protein levels
compared with SC shFABP4 mice. In sum, our data indicated
that RNAi-mediated germline knockdown of FABP4 robustly
reduced adipose tissue FABP4 gene expression and protein
levels without inducing FABP5 expression.
Knockdown of FABP4 significantly increases body weight and
whole-body fat mass in response to HFD feeding
To characterize the functional impact of FABP4 knockdown,
we analyzed the body weight of SC and HFD mice. At week
10, male shFABP4 mice fed SC displayed a significant
reduction in body weight gain compared with WT mice
on the same diet (21.4±1.6 vs 19.8±2g, respectively;
Figure 2a); this difference was maintained throughout the
remainder of the 20 week study. Half of the mice were
switched to HFD at 9 weeks of age. After 7 weeks of high fat
feeding, male shFABP4 mice showed a significant increase in
RNAi-mediated germline knockdown of FABP4
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(42.4±0.9 vs 39±1g, respectively); this difference continued
to grow throughout the length of study (51.2±0.6 vs
45.8±0.7g at 20 weeks, respectively). Female shFABP4 mice
showed a similar relative increase in body weight on HFD
and reduction in body weight gain on SC vs WT mice (data
not shown). In comparison to WT mice, shFABP4 mice
provided the HFD displayed a significant increase in weekly
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Figure 2 RNA interference (RNAi)-mediated knock down of fatty acid-
binding protein 4 (FABP4) significantly increases body weight and fat mass in
mice on high-fat diet (HFD). (a) Body weight and (b) weekly food intake per
mouse on HFD or standard chow (SC) diet (16–20 animals per group;
Po0.01). Open square and filled square represent wild-type mice and
shFABP4 mice on HFD; open triangle and filled triangle represent wild-type
mice and shFABP4 mice on SC diet, respectively. (c) Nuclear magnetic
resonance (NMR) analysis of body fat composition presented as percentage to
body weight (16–20 animals per group; Po0.001). Open bar and filled bar
represents percentage of fat mass in wild-type mice and in shFABP4 mice,
respectively. *Represents a significant difference between wild-type and
shFABP4 mice in either SC or HFD mice.
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Figure 1 Germline expression of fatty acid-binding protein 4 (FABP4) short
hairpin RNA (shRNA) (shFABP4) robustly knocks down FABP4 in adipose tissue
without affecting FABP5 expression. Gene expression analysis was performed
in adipose tissue from mice on standard chow (SC) and high-fat diet (HFD).
Real-time PCR analysis of (a) FABP4 and (b) FABP5 expression relative to wild-
type SC mice (16–20 animals per group). (c) ELISA analysis of FABP4 protein
levels in adipose tissue relative to wild-type SC mice (16–20 animals per
group). Expression levels in wild-type SC mice were artificially set to 100.
Open bar and filled bar represents gene expression levels in wild-type mice
and in shFABP4 mice, respectively. *Represents a significant difference
between wild-type and shFABP4 mice in either SC or HFD mice (Po0.001).
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International Journal of Obesityfood intake starting from 13 week (data not shown), which is
4 weeks after the commencement of HFD feeding (Figure 2b).
There was no significant difference in food intake between
shFABP4 and WT mice on SC.
We examined the whole body fat mass of our different
mouse cohorts using the quantitative nuclear magnetic
resonance methodology described in the ‘Materials and
methods’ section. There was no difference in the body fat
content between shFABP4 and WT mice on SC. However, as
expected, WT mice fed the HFD demonstrated an
almost fourfold increase in fat mass compared with SC mice
(46.3±0.8 vs 12.4±0.8%, respectively; Figure 2c). Further-
more, shFABP4 mice on HFD showed a marked increase
in fat mass vs WT HFD mice (52.1±1.1 vs 46.3±0.8%,
respectively; Figure 2c). A different set of mice (n¼7–10 per
group) was studied at Mouse Clinical Institute (MCI) (Parc
d’Innovation, France) with consistent results in body weight
and fat mass. Taken together, our data indicated that
knockdown of FABP4 robustly increases body weight and
fat mass in HFD mice.
Knocking down FABP4 does not affect glucose tolerance or
insulin sensitivity
To investigate the potential physiological effects of FABP4
knockdown, we analyzed several key plasma metabolic
parameters in ad libitum fed or overnight fasted mice. As
shown in Table 1, both WTand shFABP4 HFD mice showed a
27-fold increase in ambient plasma insulin levels compared
with SC mice. In contrast, plasma glucose, TG and free fatty
acid levels did not differ in HFD vs SC mice. The knockdown
of FABP4 did not significantly affect plasma insulin, glucose,
TG or free fatty acid levels in ad libitum fed SC or HFD mice.
Nor did it have a notable impact on fasting plasma insulin,
glucose, TG or free fatty acid levels in SC or HFD mice
(Table 2). As knocking out FABP4 has been shown to improve
glucose tolerance and insulin sensitivity in HFD mice, we
performed oral glucose tolerance test and insulin tolerance
test. As shown in Figure 3a, knockdown of FABP4 had no
impact on glucose tolerance in HFD and SC mice. In
addition, knockdown of FABP4 by shRNA did not signifi-
cantly alter insulin sensitivity in HFD and SC mice as
measured by their response to an insulin challenge
(Figure 3b). These results were confirmed by an independent
study using a different cohort of mice. These data demon-
strated that robust knockdown of FABP4 had no effect on
glucose homeostasis or insulin action in DIO mice.
Table 1 Plasma parameter analysis in ad libitum fed mice
Fed mice Glucose
(mg per 100 ml)
Insulin
(nM)
TG
(mgml
 1)
FFA
(mM)
WT HFD 203±14 41±11 1.3±0.1 0.28±0.03
shFABP4 HFD 192±54 1 ±15 1.2±0.1 0.29±0.02
WT SC 181±81 . 5 ±0.2 1.1±0.1 0.34±0.05
shFABP4 SC 168±61 . 2 ±0.2 1.2±0.1 0.38±0.09
Abbreviations: FFA, free fatty acid; HFD, high-fat diet; SC, standard chow;
shFABP4, short hairpin RNA against fatty acid-binding protein 4 gene; TG,
triglyceride; WT, wild type.
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Figure 3 Effect of fatty acid-binding protein 4 (FABP4) knockdown on
glucose tolerance and insulin sensitivity in diet-induced obese mice. (a) Oral
glucose tolerance test and (b) insulin tolerance test were performed in high-fat
diet (HFD) and standard chow (SC) mice (8–10 animals per group, P40.05).
A bolus of glucose (2gkg
 1 of body weight) was dosed orally. Insulin
(0.5Ukg
 1 of body weight) was administered by intraperitoneal (IP) injection.
Glucose levels were monitored at 20, 40, 60, 90 and 120min by tail bleed
method. Filled triangle, filled square, open triangle and open square represent
HFD wild-type (WT), HFD shFABP4, SC WT and SC shFABP4 mice,
respectively.
Table 2 Plasma parameter analysis in overnight fasted mice
Fasted mice Glucose
(mg per 100 ml)
Insulin
(nM)
TG
(mgml
 1)
FFA
(mM)
WT HFD 207±11 3.4±0.6 0.77±0.05 0.34±0.03
shFABP4 HFD 180±12 3.8±0.4 0.78±0.04 0.43±0.03
WT SC 118±7 0.35±0.05 0.78±0.05 0.54±0.05
shFABP4 SC 130±6 0.34±0.04 0.76±0.05 0.47±0.04
Abbreviations: FFA, free fatty acid; HFD, high-fat diet; SC, standard chow;
shFABP4, short hairpin RNA against fatty acid-binding protein 4 gene; TG,
triglyceride; WT, wild type.
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FABP4 in HFD mice
Mice with genetic disruption of both FABP4 and FABP5 are
protected against the development of fatty liver, which have
significantly reduced liver TGs.
11 Further analysis demon-
strated that hepatic stearoyl coenzyme A desaturase 1 (SCD1)
levels and activity were significantly reduced. Stearoyl CoA
desaturase 1 has a key role in regulating hepatic lipogenesis,
and inhibition of this enzyme lowers liver TG content.
16 In
addition, the level of liver SCD1 expression has been shown
to regulate the plasma LCFA desaturation index.
16 Although
the mechanism by which FABP4 and FABP5 regulate hepatic
SCD1 expression is not currently understood, this associa-
tion could provide a potential biomarker for a drug
development program targeting FABP4 and FABP5.
We observed no changes in hepatic TG levels in shFABP4
mice compared with WT mice on the HFD (data not shown).
To investigate the effect of shFABP4 on plasma LCFA
desaturation index, we used gas chromatography–mass
spectrometry to analyze the saturation levels of plasma LCFA
in our different mouse groups and subsequently calculate a
desaturation index as described in the ‘Materials and
methods’ section. In ad libitum fed WT mice, HFD tended
to reduce the plasma C18:1/C18:0 desaturation index
( 30%) and significantly reduced the plasma C16:1/C16:0
desaturation index ( 40%) compared with SC mice (Figures
4a, b). In comparison with shFABP4 mice on SC, shFABP4
mice on HFD showed significantly reduced plasma C18:1/
C18:0 and C16:1/C16:0 indices (59 and 65%, respectively).
In comparison with WT mice, shFABP4 mice on SC did not
show a change in their plasma LCFA desaturation indices,
whereas shFABP4 mice on HFD tended to demonstrate a
modest reduction in C18:1/C18:0 and C16:1/C16:0 desatura-
tion indices (34 and 27%, respectively). Subsequently, we
analyzed hepatic SCD1 gene expression in our various mouse
cohorts. In comparison with WT mice fed an HFD, shFABP4
mice tended to show a reduction ( 29%) in liver SCD1
expression, whereas shFABP4 mice on SC showed no change
in SCD1 expression (Figure 4c). These data indicated that
shRNA-mediated knockdown of FABP4 only minimally
reduced the plasma LCFA desaturation indices and hepatic
SCD1 expression in HFD mice.
Effects of FABP4 knockdown on adipose tissue inflammation in
HFD mice
Recent studies have shown that FABP4 is expressed in
adipocytes and macrophages and its action in either cell
types is critical for the impact of FABP4 on systematic
metabolism.
17 To investigate the knockdown of FABP4 in
macrophages, we analyzed FABP4 expression in the liver
because it contains macrophages but not adipocytes and
FABP4 is not expressed in hepatocytes. TaqMan analysis
showed that there was an 80 or 83% reduction of FABP4
expression in SC or HFD shFABP4 liver compared with WT
mice, respectively (Figure 5a). We could not detect the
fat-specific gene, leptin, in those livers, suggesting few adipo-
cytes in the liver samples (Figure 5a). Liver samples expressed
several macrophage-specific marker genes, including CD68,
F4/80, MIP-1 and ADAM8, thus indicating the presence of
macrophages (Figure 5a).
18 Indeed, HFD mice demonstrated
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Figure 4 Effect of fatty acid-binding protein 4 (FABP4) knockdown on the
plasma long chain fatty acid (LCFA) desaturation index. In ad libitum fed mice,
plasma C18 and C16 fatty acid desaturation index was measured for the ratio
of monounsaturated FFA vs saturated FFA by gas chromatography–mass
spectrometry (GC/MS) as described in Materials and Methods section.
(a) C18:1/C18:0 and (b) C16:1/C16:0 (8–10 animals per group, P40.05).
(c) Real-time PCR analysis of liver stearoyl coenzyme A desaturase 1 (SCD1)
mRNA expression (8–10 animals per group, P40.05). Open bar and filled bar
represent wild-type mice and shFABP4 mice, respectively.
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trends toward increased F4/80 and ADAM8 compared with
SC mice, suggesting increased hepatic macrophage infiltra-
tion in HFD mice. Taken together, these data support the
conclusion that knockdown of FABP4 in liver is mainly due
to knockdown of FABP4 in macrophages.
Several lines of evidence indicate that obesity is associated
with a state of chronic, low-grade inflammation that
contributes to insulin resistance and type 2 diabetes.
19 To
investigate the impact of FABP4 knockdown on adipose
tissue inflammation, we analyzed the expression of macro-
phage markers in the adipose tissue. Leptin is highly
expressed in adipose tissue and there was a significant
increase in leptin expression in HFD mice compared with SC
mice (Figure 5b). The macrophage markers CD68, F4/80,
MIP-1, MAC-1 and ADAM8 are expressed in adipose tissue of
both SC and HFD mice. Most of these macrophage marker
genes were robustly upregulated in HFD adipose tissue,
suggesting significant macrophage infiltration in adipose
tissue of HFD mice (Figure 5b). In HFD mice, knockdown of
FABP4 significantly increased the expression of all the
macrophage markers we tested, indicating increased adipose
tissue inflammation in shFABP4 HFD mice. We did not
observe increases in the expression of these macrophage
markers in SC shFABP4 adipose tissue compared with SC WT
mice (Figure 5b). These data suggest that knockdown of
FABP4 increases adipose inflammation but does not induce
more severe insulin resistance in HFD mice.
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Figure 5 Effect of fatty acid-binding protein 4 (FABP4) knockdown on macrophages and adipose tissue inflammation. Gene expression analysis was performed in
liver and adipose tissue from mice on standard chow (SC) and high-fat diet (HFD). (a) Real-time PCR analysis of liver samples for FABP4, leptin and macrophage
marker genes: CD68 (macrosialin), F4/80 (macrophage-restricted surface glycoprotein), MIP-1 (macrophage inflammatory protein-1) and ADAM8 (disintegrin-like
metalloproteinase). (b) Real-time PCR analysis of adipose tissues for leptin and macrophage marker genes: CD68, F4/80, MIP-1, MAC-1 (macrophage antigen-1) and
ADAM8. Data represented as fold changes relative to SC wild-type WT controls. Open bar and filled bar represents gene expression levels in WT mice and in shFABP4
mice, respectively. *Represents a significant difference between WT and shFABP4 mice in either SC or HFD mice (Po0.05). ND, not detectable.
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Fatty acid-binding proteins are a family of proteins that bind
medium- and long-chain fatty acids and have been impli-
cated in intracellular fatty acid trafficking.
1,3 The two major
FABPs expressed in adipose tissue are FABP4 and FABP5; they
are also expressed in macrophage. In adipocytes, FABP4 is
more abundant than FABP5, making up as much as 1% of
their total soluble protein.
8 The exact biological functions of
FABP4 and FABP5 are not entirely understood; however,
genetic disruption of FABP4 and FABP5 has been shown to
result in improved metabolic phenotypes in obese insulin-
resistant and diabetic mouse models.
4,11,9,7 These studies
demonstrate a role for FABP4 and FABP5 in regulating insulin
sensitivity and glucose homeostasis. Such data have trig-
gered interest in developing pharmacological inhibitors of
FABP4/5 to treat metabolic disorders.
Although knockout mouse models can provide a wealth of
information regarding the physiological impact of complete
absence of a molecular target, they are often unable to clearly
indicate whether partial inhibition of a given target’s
intrinsic activity will also produce similar effects. Such
information becomes more critical in the context of trying
to identify a new drug target, as clinically useful small
molecules are unlikely to completely inhibit the function of
their target. To investigate whether a partial loss of FABP4
function will improve the pathophysiology observed in
metabolic syndrome, we created a mouse line expressing
an shRNA to FABP4. These mice displayed greatly reduced
adipose FABP4 mRNA and protein levels relative to WT mice.
In comparison with WT mice, our shFABP4 mice gained
significantly more weight on HFD, which is consistent with
the previously described phenotype of FABP4 knockout
mice.
3 As FABP4 knockout mice demonstrated an increase
in FABP5 levels, this augmentation was initially thought to
be responsible for the increase in adiposity seen in these
animals. However, forced overexpression of FABP5 was
subsequently observed to be body weight neutral in mice.
4
In the shFABP4 mice described in this study, expression of
FABP5 in adipose tissue was unchanged, yet these animals
weighed more than WT mice. These data lead us to conclude
that FABP5 did not contribute to the increase in body weight
observed in shFABP4 mice, a deduction in line with the
above FABP5 knockout mouse results. These data also hint
at a possible untoward effect of FABP4-specific inhibitors on
body weight when provided in a milieu of overnutrition.
Our results with shFABP4 mice clearly indicate that body
weight is altered in a diet-dependent manner. Although
these mice gained more weight than WT mice on an HFD,
they showed a significant reduction in body weight
compared with WT mice on SC diet containing very low
levels of dietary fat. Comparing primary cultured adipocytes
from WT and FABP4 knockout mice, the Bernlohr
20 labora-
tory demonstrated that disruption of FABP4 did not affect
the rate of fatty acid uptake or esterification. Furthermore,
this group showed that disruption of FABP4 expression
reduces basal and isoproterenol-stimulated lipolysis in
primary adipocytes.
20 They concluded that FABP4 functions
as a lipid chaperone to facilitate the movement of fatty acids
out of the cells. This function of FABP4 could provide a
potential mechanism to explain the unique body weight
phenotypes of shFABP4 mice fed different diets. When there
is an excessive lipid load, as in HFD feeding, knockdown of
FABP4 may reduce the removal of fatty acids out of
adipocytes, thereby leading to greater storage of fat in
adipose tissue and increased whole body fat mass and
weight. As HFD shFABP4 mice could store more energy in
the fat tissue, these animals could eat more to maintain daily
energy utilization. Indeed, HFD shFABP4 mice had higher
daily food intake than HFD WT mice. In contrast, during a
low lipid load, such as that provided by an SC diet,
adipocytes will only need to store very limited amounts of
lipids and should therefore require only a relatively small
amount of FABP4 protein to be fully functional. This
proposition is supported by the FABP4 gene expression in
this study. First, HFD did not induce FABP4 expression in WT
mice compared with SC-fed mice, suggesting that excess
FABP4 protein is available to handle the low lipid load in SC
mice. Second, FABP4 proteins were induced in HFD shFABP4
mice compared with SC shFABP4 mice, thereby suggesting
that the level of FABP4 protein in shFABP4 SC mice may be
enough to handle their low lipid load. Therefore, when lipid
load is increased in HFD shFABP4 mice, a compensatory
machinery is activated to provide a necessary boost in FABP4
levels. Nevertheless, it is not clear why diminishing adipose
FABP4 levels reduce body weight gain in mice fed an SC diet.
Complete ablation of FABP4, despite causing an increase in
adiposity, has been shown to result in resistance to HFD-
induced metabolic dysfunction.
3 In contrast, in our shFABP4
HFD mice, we were able to reduce adipose FABP4 protein
levels by 77%, but still did not observe significant improve-
ments in insulin sensitivity or glucose tolerance. Further
analysis indicated that adipose tissue inflammation was
increased in shFABP4 HFD mice compared with HFD WT
mice. Although shFABP4 HFD mice were more obese and
had more adipose tissue inflammation, these mice did not
develop more severe insulin resistance compared with WT
HFD mice. These data suggest that the beneficial impact in
systematic metabolism by knockdown of FABP4, if any, may
be concealed by increased adiposity and adipose tissue
inflammation. Importantly, the reduction in FABP4 levels
by shFABP4 was enough to increase the body weight on HFD
without inducing FABP5 expression. Such data do not seem
to support the use of FABP4-specific inhibitors as means to
reverse derangements in nutrient metabolism brought about
by overnutrition. However, Furuhashi et al.
1 have recently
provided the first report of the beneficial in vivo effects of a
putative FABP4 small molecule inhibitor, BMS309403. They
observed that chronic treatment with BMS309403 reduces
elevated glucose and insulin levels, and mitigates glucose
intolerance and insulin resistance in obese diabetic ob/ob
mice.
12 In addition, this small molecule did not seem to
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suggest that pharmacological inhibition of FABP4 function
may result in desirable antidiabetic outcomes, the authors
did not provide any data demonstrating the isoform
specificity of BMS309403 in these animals, thereby leaving
open the possibility that the beneficial metabolic effects they
observed were due to dual inhibition of FABP4 and FABP5.
Therefore, on the basis of previously described results with
FABP4/5 double knockout mice,
11 the above pharmacologi-
cal study
12 and the FABP4 knockdown mouse data we
provided in this study, we suggest that a dual FABP4/5
inhibitor might prove most efficacious as an antidiabetic
therapeutic agent with weight neutral or reducing effects. No
doubt, an extensive medicinal chemistry effort and a broad
array of in vitro and in vivo studies will need to be undertaken
to validate this proposition and bring forth an effective new
therapy for the treatment of type 2 diabetes patients.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
We thank Drs C Li, T Akiyama, and C Lerner for helpful
suggestions and support in this study.
References
1 Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in
metabolic diseases and potential as drug targets. Nat Rev Drug
Discov 2008; 7: 489–503.
2 Haunerland NH, Spener F. Fatty acid-binding proteinsFinsights
from genetic manipulations. Prog Lipid Res 2004; 43: 328–349.
3 Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding
protein multigene family: molecular and genetic insights into
function. Trends Endocrinol Metab 2000; 11: 175–180.
4 Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE,
Spiegelman BM. Uncoupling of obesity from insulin resistance
through a targeted mutation in aP2, the adipocyte fatty acid
binding protein. Science 1996; 274: 1377–1379.
5 Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan
MA et al. Lack of macrophage fatty-acid-binding protein aP2
protects mice deficient in apolipoprotein E against atherosclerosis.
Nat Med 2001; 7:6 9 9 – 7 0 5 .
6 Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB
et al. A genetic variant at the fatty acid-binding protein aP2
locus reduces the risk for hypertriglyceridemia, type 2 diabetes,
and cardiovascular disease. Proc Natl Acad Sci USA 2006; 103:
6970–6975.
7 Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S,
Hotamisligil GS. Improved glucose and lipid metabolism in
genetically obese mice lacking aP2. Endocrinology 2000; 141:
3388–3396.
8 Simpson MA, LiCata VJ, Ribarik Coe N, Bernlohr DA. Biochemical
and biophysical analysis of the intracellular lipid binding
proteins of adipocytes. Mol Cell Biochem 1999; 192: 33–40.
9 Maeda K, Uysal KT, Makowski L, Gorgun CZ, Atsumi G, Parker RA
et al. Role of the fatty acid binding protein mal1 in obesity and
insulin resistance. Diabetes 2003; 52: 300–307.
10 Cao H, Maeda K, Gorgun CZ, Kim HJ, Park SY, Shulman GI et al.
Regulation of metabolic responses by adipocyte/macrophage
fatty acid-binding proteins in leptin-deficient mice. Diabetes
2006; 55: 1915–1922.
11 Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KTet al.
Adipocyte/macrophage fatty acid binding proteins control inte-
grated metabolic responses in obesity and diabetes. Cell Metab
2005; 1: 107–119.
12 Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G,
Vaillancourt E et al. Treatment of diabetes and atherosclerosis
by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447:
959–965.
13 Aigner A. Cellular delivery in vivo of siRNA-based therapeutics.
Curr Pharm Des 2008; 14: 3603–3619.
14 Yang R, Wilcox DM, Haasch DL, Jung PM, Nguyen PT,
Voorbach MJ et al. Liver-specific knockdown of JNK1 up-regulates
proliferator-activated receptor gamma coactivator 1 beta and
increases plasma triglyceride despite reduced glucose and
insulin levels in diet-induced obese mice. J Biol Chem 2007;
282: 22765–22774.
15 Seibler J, Kuter-Luks B, Kern H, Streu S, Plum L, Mauer J et al.
Single copy shRNA configuration for ubiquitous gene knockdown
in mice. Nucleic Acids Res 2005; 33: e67.
16 Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M et al.
Prevention of obesity in mice by antisense oligonucleotide
inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 2005; 115:
1030–1038.
17 Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H,
Hotamisligil GS. Adipocyte/macrophage fatty acid-binding pro-
teins contribute to metabolic deterioration through actions in
both macrophages and adipocytes in mice. J Clin Invest 2008; 118:
2640–2650.
18 Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic
inflammation in fat plays a crucial role in the development
of obesity-related insulin resistance. J Clin Invest 2003; 112:
1821–1830.
19 Hotamisligil GS. Inflammation and metabolic disorders. Nature
2006; 444: 860–867.
20 Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the
adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell
lipolysis and increases cellular fatty acid levels. J Lipid Res 1999;
40: 967–972.
This work is licensed under the Creative
Commons Attribution-NonCommercial-No
DerivativeWorks3.0UnportedLicense.Toviewacopy
of this license, visit http://creativecommons.org/
licenses/by-nc-nd/3.0/
RNAi-mediated germline knockdown of FABP4
R Yang et al
225
International Journal of Obesity